Roche rheumatism drug does not reduce Covid-19 deaths
Trials showed that Actemra did not sufficiently improve the recovery of patients with Covid-19.
Copyright 2020 The Associated Press. All Rights Reserved.
Swiss pharmaceutical company Roche says a drug normally used to treat other medical conditions has failed to prove its effectiveness at alleviating the symptoms of Covid-19.
This content was published on
1 minute
swissinfo.ch/mga
Español
es
Medicamento para el reumatismo no reduce muertes por COVID-19
Phase III clinical trials on Actemra/RoActemra, in combination with Veklury, did not meet the primary goal of helping coronavirus patients recover faster and shorten their hospital stay.
There was also insufficient evidence that the drug cocktail improved mortality rates or reduced the number of patients who required ventilator or oxygen support.
“Actemra/RoActemra is not approved for the treatment of Covid-19 pneumonia,” Roche announced on Thursday. The trials did not indicate any negative side-effects, the company added.
It was hoped that the drug, which has been approved for use against rheumatoid arthritis, could control Covid-19 symptoms in patients when combined with Veklury, which is produced by US biotech firm Gilead.
But Roche added that Actemra might still play some role in the treatment of Covid-19. It said that the trial data “suggests a potential role for Actemra in treating certain patients with Covid-19 and will discuss the results with health authorities.”
Popular Stories
More
Life & Aging
Zurich: how the world capital of housing shortages is tackling the problem
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
Lufthansa set to abolish in-flight sales, SWISS to keep them
This content was published on
Perfumes, cigarettes, sunglasses: The German airline Lufthansa will no longer sell these products on long-haul flights in future. Lufthansa subsidiary Swiss is sticking to in-flight sales for the time being.
This content was published on
After a short break due to the cool weather, grass pollen is now flying in Switzerland, the Swiss Allergy Centre said on Monday.
This content was published on
Researchers have shown for the first time in Switzerland that urban greenery measurably reduces the stress levels of city dwellers.
US tariffs affect canton Zurich less than other locations
This content was published on
The Zurich cantonal government is observing the developments surrounding the US tariffs "with concern". Compared to other locations, however, Zurich should get off lightly.
This content was published on
The Alpine Museum in Bern is showing the finds of diver David Godio, who has been fishing lost objects out of the River Aare for years.
This content was published on
Healthcare costs in Switzerland rose by 2.4% in 2023. The Swiss healthcare system thus cost around CHF94 billion ($113 billion).
Karaoke tram to run through Basel during Eurovision
This content was published on
A karaoke tram will be doing the rounds in Basel during the Eurovision Song Contest (ESC). During a 90-minute journey, guests can sing and dance for free in a vintage car.
Net wealth of Swiss households rises to CHF4.8 trillion
This content was published on
Private household assets in Switzerland continued to grow strongly in 2024. The increase was driven by both the growth in financial assets and higher property assets.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche bids to co-develop potential oral Covid-19 treatment
This content was published on
The Basel-based company has partnered with Atea Pharmaceuticals to develop, manufacture and distribute the latter’s oral anti-Covid-19 treatment.
Swiss group says machines can conduct 30m virus antibody tests
This content was published on
Swiss medical diagnostics company Quotient is poised to release machines that can conduct large scale coronavirus antibody tests.
‘Anti-malaria drug can kill coronavirus’: Novartis chief
This content was published on
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.